Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib

por Dikranian, Ara, Gold, David, Bessette, Louis, Nash, Peter, Azevedo, Valderilio F., Wang, Lisy, Woolcott, John, Shapiro, Andrea B., Szumski, Annette, Fleishaker, Dona, Wollenhaupt, Jürgen
Publicado 2021

Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA...

por Winthrop, Kevin L, Citera, Gustavo, Gold, David, Henrohn, Dan, Connell, Carol A, Shapiro, Andrea B, Shi, Harry, Onofrei, Alina M, Pappas, Dimitrios A, Schulze-Koops, Hendrik
Publicado 2021

Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillanc...

por Balanescu, Andra-Rodica, Citera, Gustavo, Pascual-Ramos, Virginia, Bhatt, Deepak L, Connell, Carol A, Gold, David, Chen, All-Shine, Sawyerr, Gosford, Shapiro, Andrea B, Pope, Janet E, Schulze-Koops, Hendrik
Publicado 2022

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs

por Winthrop, Kevin L., Yndestad, Arne, Henrohn, Dan, Danese, Silvio, Marsal, Sara, Galindo, Maria, Woolcott, John C., Jo, Hyejin, Kwok, Kenneth, Shapiro, Andrea B., Jones, Thomas V., Diehl, Annette, Su, Chinyu, Panés, Julian, Cohen, Stanley B.
Publicado 2022

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry...

por Kremer, Joel M., Bingham, Clifton O., Cappelli, Laura C., Greenberg, Jeffrey D., Madsen, Ann M., Geier, Jamie, Rivas, Jose L., Onofrei, Alina M., Barr, Christine J., Pappas, Dimitrios A., Litman, Heather J., Dandreo, Kimberly J., Shapiro, Andrea B., Connell, Carol A., Kavanaugh, Arthur
Publicado 2021